Phibro Animal Health Corporation (PAHC)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$37.19−0.13%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.5B
- P/E (trailing)
- 15.3
- Forward P/E
- 9.7
- Dividend yield
- 1.3%
- 52-week range
- $28.25 – $60.08
- 52-week change
- −1.46%
- EPS (trailing)
- $2.43
- Analyst rating
- 3.0 Hold
- Next earnings
- Nov 4, 2026
Fiscal year to Jun 2026
- Revenue
- $1.5B (+17.12%)
- Net income
- $99.7M
- Operating margin
- 12.8%
- Diluted EPS
- $2.43
- Free cash flow
- $9.9M
From the company’s annual report on SEC EDGAR.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers.
Headquarters: Teaneck, United States · 2,605 employees · pahc.com